Sreelakshmi24’s Blog

where life is all about learning

Archive for March 2009

Cadila Pharmaceuticals commissioned a revolutionary research on Cardiac diseases targeted at Asymptomatic Healthy people

leave a comment »

To launch a product that will considerably reduce the mortality due to sudden cardiac disorder, world wide

 

 

Ahmedabad Based Pharma major Cadila Pharmaceuticals, one of the most reputed, Research based, Tech savvy pharmaceutical company in collaboration with McMaster University of Hamilton, Canada, has done a revolutionary research targeted to Asymptomatic Healthy people.

 

Shri I. A. Modi, Chairman Cadila Pharmaceuticals said, “Cadila Pharmaceuticals has carved a niche for itself by being the front runner in introducing research driven innovative products for the benefit of mankind. Worldwide Cardio Vascular diseases are the leading cause of death and disability. Despite the best of diagnostic and therapeutic approaches, the challenge to decrease mortality and morbidity stands, because cardiac malfunction does not necessarily happen in patients with symptoms. Various therapies are currently available for secondary prophylaxis of cardiovascular diseases but none for primary prophylaxis.
Studies show that Cardio Vascular death burden in developed countries were 5.3 million in the year 1990 whereas in developing countries it was 7-8 million. With the burgeoning epidemic of CVD, especially in low income countries, effective preventive strategies need to be urgently implemented. Cadila Pharma took it as a challenge to develop a therapy to address primary prophylaxis.”

Mr J.P Parswani, President, Cadila Pharmaceuticals Limited commented, “A research team comprising of 57 cardiologists, led by Dr Salim Yusuf, Dean Cardiovascular Services worked for two years at McMaster University, Hamilton to make the hypothesis a success. The Research findings of the same would be revealed by Dr Salim Yusuf on March 30th 2009 at the American College of Cardiology, Orlando, in presence of more than 25,000 cardiologists all over the world. The research team has come up with a new therapy, a new approach, a comprehensive treatment that is going to set a benchmark in the treatment of Cardio Vascular diseases. The launch of this product marks Cadila’s contribution to science, academics and mankind. The Product is not just
a substitute for lifestyle management, but it complements the same.The product would help to bring down the cardiovascular morbidity and mortality.”

Dr Arun Maseeh, Vice President – Medical Services, is of the opinion, “Risk prevention in CVD can be approached from two levels: at the individual level and at population level. And two interventions are available to reduce risk factor levels, namely lifestyle modifications and drugs. Unfortunately lifestyle modifications related interventions have not largely been successful, as individuals were targeted rather that entire population with a few exceptions. It is therefore time to seriously consider drugs to halt the rapid advancement of CVD related mortality, especially in developing countries. The best results are obtained when multiple risk factors a re targeted at the same time. We have tested the hypothesis of Wald and Law, comprehensively in a multicentre, randomized, controlled, double-blind trial – The Indian Polycap Study (TIPS). The trials conducted in 53 hospitals all over India on 2053 healthy people. The Indian Coordinating Center was St. John’s Medical College, Bangalore, and the International Coordinating Center was Population Health Research Institute HHS and McMaster University, Hamilton, Canada.”

For further information please contact:    

medical@cadilapharma.co.in


Advertisements

Lupin acquires majority stake in Multicare Pharmaceuticals Philippines, Inc

leave a comment »

Strengthens its position in the ASEAN market

Lupin Limited recently announced the acquisition of a 51 percent stake in Multicare Pharmaceuticals Philippines, Inc (MC) of Philippines. MC is a premium branded generics company with a strong position in the women’s health and child care segment. The company reported revenues of Php 272 Mill (approx. USD 6mn) for the year ending December 2008. The acquisition has been made with internal cash accruals by Lupin.

This acquisition, which is Lupin’s sixth since 2008, marks the company’s entry into the USD 2.5 bn pharmaceuticals market in Philippines, currently dominated by multinational companies. Under the agreement, Mr. Romeo Sy, founder, MC will continue to lead the company as President.

Commenting on the development, Dr. Kamal Sharma, Managing Director, Lupin Limited
said, “This is a very positive step ahead for Lupin to establish its stronghold as a top league generics company in the promising market of Philippines in the ASEAN Region. We have seen immense success with our previous acquisitions, all of which have been profitable. Taking this philosophy forward, we believe that MC is a strategic fit in Lupin’s business model. We will continue to focus and leverage on operational efficiencies and capitalize on synergies between the two companies to drive revenues at robust growth rates from the region in the near term.”

Multicare President, Romeo Sy said that the partnership will be of considerable benefit to MC’s position in the generics industry locally. “The equity acquisition by Lupin gives us increased access to international research and development, world-class manufacturing capabilities which will further strengthen our local position”, he said.

MC, with field strength of about 140 people enjoys a commendable franchise with the medical fraternity and harbors strong distribution alliances. The dedicated Global Business Development department of Lupin will ensure continual exposure to international companies and product opportunities. Lupin is amongst the fastest growing pharmaceutical company in India with dedicated R&D facilities and is vertically integrated with presence in many global markets. This strategic partnership will provide significant benefits for both parties. MC will gain access to Lupin’s existing product pipeline and manufacturing expertise, while Lupin will gain access to the established brands and supply chains in Philippines.

Walter Vieira wins Lifetime Achievement Award at the Indy’s

leave a comment »

Mr. Walter Vieira, Asia’s first elected Chairman of the International Council of Management Consultants, was awarded the Lifetime Achievement Award at The Third edition of the Indy’s – Awards for Excellence in Marketing communications, Advertising & Branding function was held at the Taj Lands End in Mumbai recently. This was supported by the Indira Group of Institutions and Exchange 4 media.com.

Mr Vieira is a senior marketing consultant, who pioneered marketing consultancy in India by founding – Marketing Advisory Services in 1975.

Mr. Vieira was also awarded the Lifetime Achievement Award in 2005 by the Institute of Management Consultants of India for his services to the consulting profession over 30 years.

Commenting on this accolade Mr. Vieira said, “It is indeed a great honour to have received such accreditation. It is nice to know that one’s work does not go unnoticed. I am greatly humbled by this and would like to thank all those that have helped me throughout the years to get to this point.”

Written by sreelakshmi

28 March, 2009 at 2:16 pm

Specialised services by DHL especially for life sciences and clinical trial products

leave a comment »

Temperature Control Logistics

Identifying life science industry’s requirement for specialized solutions in transportation of sensitive commodities, which require temperature-controlled movement and servicing, DHL developed customized solutions for all life science’s projects and clinical trials, with dedicated life sciences team and specialized TAPA certified infrastructure. DHL has the operational expertise to provide customized solutions; IATA validated packaging and other value added services which ensure that the product is delivered under the right conditions and within compliance.

DHL Express is a solution provider with specialized Infrastructure in India for temperature controlled shipments, packaging, freezers, coolants and dry Ice availability in all major locations along with temperature loggers which assist in understanding the temperature variations which happen during transit. With its vast network coverage in India, DHL offers services to 97+ countries across all continents.

 DHL’s validated packaging for various temperature ranges offers temperature control and stability for the entire transit period of the shipment. Packaging not only ensures product protection, but is also environment friendly and recyclable. Proactive customer service support, project setup and management, value added services like temperature logger readings post delivery are additional merits.

 To further the comfort there are dedicated resources in sales, marketing and IT team. Ahead of time, IT solutions aid track, trace and generate customized reports on status of shipments.

 
 

For further information you can visit http://www.dhl.co.in

Fortis announces aggressive plans for Clinique Darné now renamed ‘Fortis Clinique Darné’

leave a comment »

CIEL and Fortis Healthcare, who have recently announced a strategic tie up to pick up majority stake in Mauritius’ largest private hospital, Clinique Darné, today unveiled aggressive plans for the hospital. Fortis Healthcare, who have the operations and management contract for the hospital, have extensive plans to enhance the quality of healthcare services being provided. Dr. The Hon Navinchandra Ramgoolam, G.C.S.K. Prime Minister, Minister of Defense and Home Affairs graced the occasion and unveiled Fortis Clinique Darné‘s new logo. Mr. Shivinder Mohan Singh, Managing Director, Fortis Healthcare, Mr. Bhavdeep Singh, Chief Executive Officer, Fortis Healthcare and Mr. Gérald De Senneville, CIEL were present at the occasion.                   

Fortis Healthcare, India’s fastest growing healthcare delivery network plans to utilize its experience and expertise to upgrade and expand Fortis Clinic Darné in a two phased manner.

  • In phase I, the company will make an investment of MUR 66 million of a total of MUR 165 Mn invested and upgrade the current facility which will involve introduction of new specialties and upgradation of existing specialties to tertiary care level.
  • In Phase II, the company, utilizing the six acre land available, will expand the facility to become a 400-bedded super speciality hospital providing comprehensive medical services.

To support the upgradation of medical program, there will be introduction of a high end Critical Care Department. This will allow treatment of more complicated and high end cases. There will be introduction of high end Surgical ICU, Medical ICU and Pediatric ICU. Fortis also plans to introduce a Neonatal ICU which will be of tremendous support to the birthing program in the hospital. These Critical Care Units will meet an important need for people of Mauritius. Along with these, there will be extensive scaling up of Emergency Medicine and Ambulance Services. There will be introduction of comprehensive range of diagnostic services including high end Radiology & Laboratory services. While Clinique Darne was the first private player to introduce Cardiac Care in Mauritius, its Cardiac Program will receive significant strength and will be enhanced using the expertise of Fortis. Today Fortis runs the “Fortis Escorts Cardiac Program” which is one of the largest Cardiac Programs in the world.

Post the investment and creation of state of art super speciality healthcare hub, Mauritians would not be required to travel abroad for high end treatment and the hospital will also attract patients from neighbouring African countries. Fortis, known for its clinical excellence and compassionate patient care, will bring in its clinical and management expertise to further enhance the scope and the quality of services available at Fortis Clinique Darné.

According to Mr. Gérald De Senneville, CIEL, “Fortis is a renowned and highly respected name in the Indian healthcare space with significant contribution made to the sector. We are very proud of this association which has come up after considerable research. We are confident and optimistic that the experience and expertise that Fortis will bring to Fortis Clinique Darné will add immense value not only to the hospital but also to the Mauritian healthcare sector.”

Mr. Raj Gore, Chief Operating Officer of Fortis Clinique Darné further added that, “As a trusted health partner, Clinique Darné has always taken the leadership role to reinvent itself to provide the best of healthcare to the people of Mauritius. The association with an eminent group like Fortis is another milestone in the same tradition. We are very confident about adding real value to the clinical as well as hospital services. Our patients would undoubtedly be the first beneficiary of this.”

While commenting on his plans for Fortis Clinique Darné, Mr. Shivinder Mohan Singh said, “We are excited to be in Mauritius which has a strong cultural and historical connect with India. We are committed to bringing our healthcare expertise for betterment of healthcare standards not only in Fortis Clinique Darné but to the entire Mascaranes and beyond.”

Fortis follows Clinical Protocols found in the best Global Hospitals and has the honour of having a JCI accredited hospital and four hospitals having the coveted NABH accreditation issued by the Quality Council of India. Fortis will bring these protocols to Fortis Clinique Darné for significantly enhancing patient care.

Additionally, Fortis will introduce its’ Fortis Operating System (FOS), designed to provide uniform experience to patients across the Fortis network. FOS benchmarks the quality of services delivered at each patient interface point and creates systems and processes to deliver the same to provide the best in patient care.

Fortis will also continuously train and educate medical, paramedical, nursing and support services staff to ensure high quality service levels.

LifeCell launches Cord Tissue Banking in India

leave a comment »


LifeCell International – India’s first & the largest stem cell banking service provider and a pioneer in stem cell research, technology & therapy – announced the launch of Umbilical cord tissue banking service in India. The technology to harness the potential of Umbilical Cord Tissue, a rich source of Mesenchymal stem cells was developed in-house at the LifeCell R&D center at Chennai., India. With this launch, LifeCell achieved a considerable technology landmark in the field of Regenerative science & healthcare industry in India.

Mesenchymal Stem Cells (MSCs) from bone marrow have been at the forefront of therapeutic strategies for a number of hitherto incurable ailments like Heart Disease, Type I Diabetes, Crohn’s Disease, GVHD, Osteoarthritis and Stroke. Further, MSCs from Cord tissue showed additional therapeutic potential in animal models to treat Parkinsonism, Skeletal muscle injury, Limb ischemia, Retinal nerve degeneration. Hence, these cord tissue MSCs appear to be superior to bone marrow MSCs and can be a potential substitute for them.

Advantages of Mesenchymal Stemcells:

In a unit population of cells MSCs in the umbilical cord tissue are present in much higher numbers when compared with the bone marrow. These cells have shorter doubling time. Also the HLA ABC antigens are less of an issue with cord MSCs when compared with bone marrow MSCs.

Talking at the occasion,
Mr. Mayur Abhaya, President and Executive Director, LifeCell International, said, “We at LifeCell are very excited about this landmark achievement that we have made at our R&D center, by developing the technology to harvest and store Umbilical Cord Tissue in India. With additional service of cord tissue banking, , clinical trials, R&D, therapy solutions we are the only company in India providing comprehensive stem cells solutions. This will give us a competitive edge to tap the potential market. In a country like India with over 40 million births every year, the potential is immense and we see a huge opportunity ahead. We envision a 30% percent growth in our enrolments by 2010. Our revenue for this year is expected to close by Rs.400 Million.”

According to Dr. Ajit, Chief Scientific Officer, LifeCell International, “Previously, after the collection of the umbilical cord blood, the remaining solid cord tissue was normally discarded. However, this cord tissue is a rich source of Mesenchymal stem cells (MSCs) and we have invested two years of time in developing and validating a proprietary technology at our in-house R&D center for collection and storage of the cord tissue. These MSCs from cord tissue are superior to bone marrow MSCs, as these cells are fetal in nature and therefore more robust. Besides, the collection process is non invasive, painless and usually devoid of infection.” Added Dr. Ajit

Over the conversation about the awareness and acceptance of stem cells in India Mr. Mayur added, “Recent success stories of stem cells, daily news on research findings and breakthrough in clinical trials etc., are validating the potential of stem cells thereby increasing the demand for storing the baby’s stem cell for future potential use. The medical fraternity has been playing a vital role in supporting and spreading knowledge and awareness on this concept.”

Storing and cost at LifeCell

Customers who want to store their cord tissue have a range of options with LifeCell. They may choose to bank the processed stem cells from the Cord Tissue for a ready use or store the cord tissue which can be used to harvest stem cells later for therapy.

Preserving the cord tissue comes as a package along with cord blood banking service of LifeCell at a cost of Rs.44,600/- for the first year and Rs.3,500/- every year as annual storage fee. However, if the client prefers to process the cord tissue and store the harvested stem cells, the process will cost Rs.63,100/- for the first year and Rs.5,500/- every year as annual storage fee. Both these options include processing and cryo-preserving the cord blood stem cells which is the basic service. Clients could also go for the option of one-time storage fee of Rs.79,000/- upfront for storing cord blood and cord tissue and Rs.1,17,500 for storing cord blood along with processing of cord tissue.

LifeCell’s key differentiator has been quality and service and with a technology tie-up with the Cryo-Cell International, the world’s first stem cell bank, LifeCell has the expertise of technology to maintain the best quality which has also been acknowledged and accredited by AABB. LifeCell offers round-the-clock service and is the only stem cell bank in India offering this service to over 40 centres in India & abroad.

 


INCREASING THREAT OF TUBERCULOSIS IN INDIA

leave a comment »

Every year 24th March is celebrated as World TB day. Even today Tuberculosis is a leading cause of death in India. Know more about this deadly disease from this article authored by
Dr. Shamma Shetye, HOD, Microbiology, Metropolis Health Services(I) Ltd.

India has more new TB cases annually than any other country, ranking first among the 22 high-burden TB countries worldwide according to the WHO Global TB Report 2006. TB remains one of the leading infectious causes of mortality in India, resulting in 364,000 deaths annually. There were more than 1.8 million new TB cases in India in 2004, representing over one-fifth of all TB cases worldwide. The estimated incidence rate in 2004 was 168 per 100,000 people.

The proportion of tuberculosis cases co-infected with human immunodeficiency virus (HIV) was also found to be rising. The association with HIV and increasing multi drug resistant tuberculosis (MDRTB) appears to be a serious issue, especially for the developing nations. Around 10% of people infected with TB actually develop the disease in their lifetimes, but this proportion is changing as HIV severely weakens the human immune system and makes people much more vulnerable. TB causes more deaths among women than all causes of maternal mortality combined, and more than 900 million women are infected with TB worldwide. Once infected with TB, women of reproductive age are more susceptible to developing TB disease than men of the same age. Women in this age group are also at greater risk of becoming infected with HIV.

You are at risk, if you have:

  • Lower Immunity
  • Close contact with someone with infectious TB
  • Age, older adults
  • Substance Abuse
  • Malnutrition
  • Lack of Medical Care

Some of the signs & symptoms to keep a watch for:

  • Unintended weight loss
  • Fatigue
  • Slight fever
  • Night Sweats
  • Chills
  • Loss of appetite
  • Pain with breathing or coughing

SOME MYTHS AND TRUTH ABOUT TB

  • Myth – TB is a life-threatening disease
  • Truth – TB can be cured by taking a course of medicine
  • Myth – You can become infected by TB by touching someone who has it or being with someone who has it for a few minutes
  • Truth – TB is transmitted only by prolonged close contact with coughing infectious patients
  • Myth – If someone has TB they are infectious
  • Truth – TB patients who have taken their treatment for 2 weeks and are still taking treatment are usually not infectious
  • Myth – Only the poor and malnourished get TB
  • Truth – Anyone can get TB rich or poor and become unwilling host to bacteria
  • Myth – Once you have TB you are doomed and cannot get treated
  • Truth – TB treatment is freely available, and correct treatment cures the vast majority of cases

Rapid Diagnosis of TB is important for the treatment of the individual patient and to implement appropriate public health precautions. Timely diagnosis at reputed and accredited laboratories can help in determining the infectiousness and assess drug susceptibility. Since the treatment is prolonged the tests have to be done periodically to analyze the situation and path of treatment. Once TB is diagnosed, tests are conducted every two to three months till the patient is declared completely cured. The RNTCP (Revised National TB Control Programme) has also laid guidelines to ensure consistency in treatment.

Key tests on TB offered by Metropolis Health Services

Metropolis provides the widest test menu for TB, costs ranging between Rs. 100 to Rs.4000. Metropolis maintains high standards of quality and is a NABL, CLIA & CAP Accredited Laboratory. The quality of equipments and standardized reagents ensure the high accuracy of the results.

  1. Microscopy– A basic screening test with a turnaround time of a day, rapid and the first step to diagnosis of TB.
  2. Culture A definitive diagnosis of TB that requires identification of the mycobacterium tuberculosis form a specimen. The microbe is made to grow in artificial medium to analyze the strain. The turnaround time is between 3-6 weeks.
  3. Automated liquid culture/ Rapid culture- This is also a form of culture wherein the turnaround time is brought down to as low as 10 – 15 days. The microbes are made to grow in liquid medium which is fully automated.
  4. Drug susceptibility- This is a drug sensitivity test, primarily to determine that whether the drugs are reacting in the proper direction or not. This is usually recommended after the treatment has begun, ideally 2-3 months from detection.
  5. Molecular methods- Turnaround time is as low as a day, it largely deals with rapid detection of the infection, directly from specimens. This is highly sensitive nad specific for the diagnosis of M. TB complex.
  6. Quanteferon TB Gold test- A higly advanced and gold standard test. It is a whole blood test used as an aid for diagnosing different strains of TB including latent tuberculosis infection ( LTBI). This has been approved by FDA in 2005.
  7. DNA probe- To figure out the strain of the mycobacterium tuberculosis, it is a step forward in identifying the culture.

 


Written by sreelakshmi

25 March, 2009 at 8:09 pm